IT201900014568A1 - Topical preparation for dermatological treatments - Google Patents
Topical preparation for dermatological treatments Download PDFInfo
- Publication number
- IT201900014568A1 IT201900014568A1 IT102019000014568A IT201900014568A IT201900014568A1 IT 201900014568 A1 IT201900014568 A1 IT 201900014568A1 IT 102019000014568 A IT102019000014568 A IT 102019000014568A IT 201900014568 A IT201900014568 A IT 201900014568A IT 201900014568 A1 IT201900014568 A1 IT 201900014568A1
- Authority
- IT
- Italy
- Prior art keywords
- preparation
- cannabidiol
- oil
- ozonated
- preparation according
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 60
- 238000011282 treatment Methods 0.000 title claims description 12
- 230000000699 topical effect Effects 0.000 title claims description 9
- 239000003921 oil Substances 0.000 claims description 41
- QHMBSVQNZZTUGM-UHFFFAOYSA-N Trans-Cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-UHFFFAOYSA-N 0.000 claims description 32
- QHMBSVQNZZTUGM-ZWKOTPCHSA-N cannabidiol Chemical compound OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)=C)CCC(C)=C1 QHMBSVQNZZTUGM-ZWKOTPCHSA-N 0.000 claims description 32
- 229950011318 cannabidiol Drugs 0.000 claims description 32
- ZTGXAWYVTLUPDT-UHFFFAOYSA-N cannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1C1C(C(C)=C)CC=C(C)C1 ZTGXAWYVTLUPDT-UHFFFAOYSA-N 0.000 claims description 32
- PCXRACLQFPRCBB-ZWKOTPCHSA-N dihydrocannabidiol Natural products OC1=CC(CCCCC)=CC(O)=C1[C@H]1[C@H](C(C)C)CCC(C)=C1 PCXRACLQFPRCBB-ZWKOTPCHSA-N 0.000 claims description 32
- 239000004480 active ingredient Substances 0.000 claims description 19
- 150000003505 terpenes Chemical class 0.000 claims description 15
- 235000007586 terpenes Nutrition 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 13
- 239000006071 cream Substances 0.000 claims description 11
- 239000000839 emulsion Substances 0.000 claims description 8
- 239000002018 neem oil Substances 0.000 claims description 8
- 238000010521 absorption reaction Methods 0.000 claims description 7
- 239000004615 ingredient Substances 0.000 claims description 7
- 238000005063 solubilization Methods 0.000 claims description 5
- 230000007928 solubilization Effects 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 235000019198 oils Nutrition 0.000 description 37
- 235000015112 vegetable and seed oil Nutrition 0.000 description 17
- 239000000126 substance Substances 0.000 description 12
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 11
- UAHWPYUMFXYFJY-UHFFFAOYSA-N beta-myrcene Chemical compound CC(C)=CCCC(=C)C=C UAHWPYUMFXYFJY-UHFFFAOYSA-N 0.000 description 8
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 8
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 210000003491 skin Anatomy 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 230000037303 wrinkles Effects 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 5
- -1 ethylhexyl Chemical class 0.000 description 5
- 238000006385 ozonation reaction Methods 0.000 description 5
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 4
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 4
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 4
- WRMNZCZEMHIOCP-UHFFFAOYSA-N 2-phenylethanol Chemical compound OCCC1=CC=CC=C1 WRMNZCZEMHIOCP-UHFFFAOYSA-N 0.000 description 4
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 4
- 201000004624 Dermatitis Diseases 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 4
- 235000001466 Ribes nigrum Nutrition 0.000 description 4
- 241001312569 Ribes nigrum Species 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- VYBREYKSZAROCT-UHFFFAOYSA-N alpha-myrcene Natural products CC(=C)CCCC(=C)C=C VYBREYKSZAROCT-UHFFFAOYSA-N 0.000 description 4
- 230000001153 anti-wrinkle effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- 235000001510 limonene Nutrition 0.000 description 4
- 229940087305 limonene Drugs 0.000 description 4
- 229930007744 linalool Natural products 0.000 description 4
- GRWFGVWFFZKLTI-UHFFFAOYSA-N α-pinene Chemical compound CC1=CCC2C(C)(C)C1C2 GRWFGVWFFZKLTI-UHFFFAOYSA-N 0.000 description 4
- NPNUFJAVOOONJE-ZIAGYGMSSA-N β-(E)-Caryophyllene Chemical compound C1CC(C)=CCCC(=C)[C@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-ZIAGYGMSSA-N 0.000 description 4
- OPJWPPVYCOPDCM-UHFFFAOYSA-N 2-ethylhexyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(CC)CCCC OPJWPPVYCOPDCM-UHFFFAOYSA-N 0.000 description 3
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 3
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 3
- 230000003466 anti-cipated effect Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 210000002615 epidermis Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000004006 olive oil Substances 0.000 description 3
- 235000008390 olive oil Nutrition 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 2
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 2
- GRWFGVWFFZKLTI-IUCAKERBSA-N 1S,5S-(-)-alpha-Pinene Natural products CC1=CC[C@@H]2C(C)(C)[C@H]1C2 GRWFGVWFFZKLTI-IUCAKERBSA-N 0.000 description 2
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 2
- 241000465531 Annea Species 0.000 description 2
- 240000004355 Borago officinalis Species 0.000 description 2
- 235000007689 Borago officinalis Nutrition 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 description 2
- GLZPCOQZEFWAFX-UHFFFAOYSA-N Geraniol Chemical compound CC(C)=CCCC(C)=CCO GLZPCOQZEFWAFX-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 240000002024 Gossypium herbaceum Species 0.000 description 2
- 235000004341 Gossypium herbaceum Nutrition 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 244000042664 Matricaria chamomilla Species 0.000 description 2
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 2
- 244000025272 Persea americana Species 0.000 description 2
- 235000011236 Persea americana var americana Nutrition 0.000 description 2
- 240000006365 Vitis vinifera Species 0.000 description 2
- 235000014787 Vitis vinifera Nutrition 0.000 description 2
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 2
- MVNCAPSFBDBCGF-UHFFFAOYSA-N alpha-pinene Natural products CC1=CCC23C1CC2C3(C)C MVNCAPSFBDBCGF-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- NPNUFJAVOOONJE-UHFFFAOYSA-N beta-cariophyllene Natural products C1CC(C)=CCCC(=C)C2CC(C)(C)C21 NPNUFJAVOOONJE-UHFFFAOYSA-N 0.000 description 2
- 229940036350 bisabolol Drugs 0.000 description 2
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- NPNUFJAVOOONJE-UONOGXRCSA-N caryophyllene Natural products C1CC(C)=CCCC(=C)[C@@H]2CC(C)(C)[C@@H]21 NPNUFJAVOOONJE-UONOGXRCSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 229940093528 cetearyl ethylhexanoate Drugs 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 210000004207 dermis Anatomy 0.000 description 2
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 229940100524 ethylhexylglycerin Drugs 0.000 description 2
- 210000001097 facial muscle Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000005456 glyceride group Chemical group 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 235000002532 grape seed extract Nutrition 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- NUHSROFQTUXZQQ-UHFFFAOYSA-N isopentenyl diphosphate Chemical group CC(=C)CCO[P@](O)(=O)OP(O)(O)=O NUHSROFQTUXZQQ-UHFFFAOYSA-N 0.000 description 2
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229940044591 methyl glucose dioleate Drugs 0.000 description 2
- 235000013923 monosodium glutamate Nutrition 0.000 description 2
- WURFKUQACINBSI-UHFFFAOYSA-M ozonide Chemical compound [O]O[O-] WURFKUQACINBSI-UHFFFAOYSA-M 0.000 description 2
- 229940101267 panthenol Drugs 0.000 description 2
- 235000020957 pantothenol Nutrition 0.000 description 2
- 239000011619 pantothenol Substances 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 229940068968 polysorbate 80 Drugs 0.000 description 2
- CBIDRCWHNCKSTO-UHFFFAOYSA-N prenyl diphosphate Chemical compound CC(C)=CCO[P@](O)(=O)OP(O)(O)=O CBIDRCWHNCKSTO-UHFFFAOYSA-N 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000009759 skin aging Effects 0.000 description 2
- 229940073490 sodium glutamate Drugs 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 2
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- AJBZENLMTKDAEK-UHFFFAOYSA-N 3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysene-4,9-diol Chemical compound CC12CCC(O)C(C)(C)C1CCC(C1(C)CC3O)(C)C2CCC1C1C3(C)CCC1C(=C)C AJBZENLMTKDAEK-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 244000144730 Amygdalus persica Species 0.000 description 1
- 244000003027 Bergamotto Species 0.000 description 1
- 235000003880 Calendula Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- WTEVQBCEXWBHNA-UHFFFAOYSA-N Citral Natural products CC(C)=CCCC(C)=CC=O WTEVQBCEXWBHNA-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000276331 Citrus maxima Species 0.000 description 1
- 235000001759 Citrus maxima Nutrition 0.000 description 1
- 240000003791 Citrus myrtifolia Species 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000009088 Citrus pyriformis Nutrition 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 244000295848 Citrus x nobilis Species 0.000 description 1
- 235000017102 Citrus x nobilis Nutrition 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 239000005792 Geraniol Substances 0.000 description 1
- GLZPCOQZEFWAFX-YFHOEESVSA-N Geraniol Natural products CC(C)=CCC\C(C)=C/CO GLZPCOQZEFWAFX-YFHOEESVSA-N 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 240000007232 Illicium verum Species 0.000 description 1
- 235000008227 Illicium verum Nutrition 0.000 description 1
- RRHGJUQNOFWUDK-UHFFFAOYSA-N Isoprene Chemical group CC(=C)C=C RRHGJUQNOFWUDK-UHFFFAOYSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 241000208204 Linum Species 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 244000237986 Melia azadirachta Species 0.000 description 1
- 235000013500 Melia azadirachta Nutrition 0.000 description 1
- 206010049816 Muscle tightness Diseases 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 235000002725 Olea europaea Nutrition 0.000 description 1
- 241001483078 Phyto Species 0.000 description 1
- 235000006040 Prunus persica var persica Nutrition 0.000 description 1
- 235000019486 Sunflower oil Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000002225 anti-radical effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940119162 calendula officinalis flower extract Drugs 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940043350 citral Drugs 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000000172 cytosol Anatomy 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- WTEVQBCEXWBHNA-JXMROGBWSA-N geranial Chemical compound CC(C)=CCC\C(C)=C\C=O WTEVQBCEXWBHNA-JXMROGBWSA-N 0.000 description 1
- 229940113087 geraniol Drugs 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 229940038864 hydrogenated olive oil unsaponifiables Drugs 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 239000000944 linseed oil Substances 0.000 description 1
- 235000021388 linseed oil Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- BFBPISPWJZMWJN-UHFFFAOYSA-N methyl 2-[(7-hydroxy-3,7-dimethyloctylidene)amino]benzoate Chemical compound COC(=O)C1=CC=CC=C1N=CCC(C)CCCC(C)(C)O BFBPISPWJZMWJN-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 230000037125 natural defense Effects 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 235000019645 odor Nutrition 0.000 description 1
- 229940060184 oil ingredients Drugs 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229940067107 phenylethyl alcohol Drugs 0.000 description 1
- 230000008832 photodamage Effects 0.000 description 1
- 230000003711 photoprotective effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000009993 protective function Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 239000010667 rosehip oil Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000002600 sunflower oil Substances 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Description
DESCRIZIONE dell'Invenzione Industriale dal titolo: “Preparato ad uso topico per trattamenti dermatologici” DESCRIPTION of the Industrial Invention entitled: "Preparation for topical use for dermatological treatments"
DESCRIZIONE DESCRIPTION
La presente invenzione ha per oggetto un preparato ad uso topico per trattamenti dermatologici comprendente come principale principio attivo Cannabidiolo. The present invention relates to a preparation for topical use for dermatological treatments comprising Cannabidiol as the main active ingredient.
In particolare l’invenzione si riferisce ad un settore di cosmetici-farmaci, settore cosmeceutico, che interessano la cura non solo di malattie, ma anche della propria immagine: ciò che nel secolo scorso non era parte del concetto di salute, ora infatti viene trasformato in vera e propria malattia o almeno in condizioni da trattare come si farebbe per un diabete o un’ulcera. In particular, the invention refers to a cosmetic-pharmaceutical sector, a cosmeceutical sector, which involves the treatment not only of diseases, but also of one's own image: what in the last century was not part of the concept of health, is now in fact transformed in actual disease or at least in conditions to be treated as you would for a diabetes or an ulcer.
L’Organizzazione Mondiale della Sanità sostiene infatti che il concetto di salute debba essere intesto come "stato di completo benessere fisico, psichico e sociale e non semplice assenza di malattia", proprio per enfatizzare il concetto che non è l’assenza di malattia che stabilisce che un organismo sia in salute, ma piuttosto un benessere generale. Indeed, the World Health Organization argues that the concept of health must be understood as a "state of complete physical, mental and social well-being and not simply the absence of disease", precisely to emphasize the concept that it is not the absence of disease that establishes that an organism is healthy, but rather a general well-being.
Particolarmente sentito è il problema delle rughe la cui comparsa rappresenta il segno dell’invecchiamento cutaneo e del foto-danneggiamento dei raggi solari. Particularly felt is the problem of wrinkles whose appearance is the sign of skin aging and photo-damage of the sun's rays.
La cute è costituita da vari elementi tra cui l’epidermide ed il derma: la prima svolge una funzione protettiva del corpo mentre la seconda fa da sostegno all’epidermide ed è responsabile della tonicità della cute. The skin is made up of various elements including the epidermis and the dermis: the first performs a protective function of the body while the second supports the epidermis and is responsible for the tone of the skin.
La struttura compatta del derma è dovuta alla presenza di fibre collagene e fibre elastiche, la cui perdita è uno dei principali fattori di invecchiamento. Col tempo, per le alterazioni a carico del tono e dell’elasticità, la cute non è più in grado di rilasciarsi e rimangono incise le prime depressioni che evolvono progressivamente con l’invecchiamento della cute. The compact structure of the dermis is due to the presence of collagen fibers and elastic fibers, the loss of which is one of the main factors of aging. Over time, due to changes in tone and elasticity, the skin is no longer able to release and the first depressions remain incised and progressively evolve with skin aging.
La contrazione dei muscoli del volto è un altro fattore essenziale e predominante nella formazione delle rughe. La contrazione cronica dei muscoli del volto forma, con il tempo, pieghe visibili sul viso anche quando questo è rilassato e con il passare degli anni le rughe tendono rimanere anche “a riposo”. The contraction of the muscles of the face is another essential and predominant factor in the formation of wrinkles. Over time, the chronic contraction of the facial muscles forms visible folds on the face even when it is relaxed and wrinkles tend to remain “at rest” over the years.
Per ridurre significativamente le rughe e ritrovare una pelle più liscia, bisogna agire sul meccanismo principale responsabile della formazione delle rughe e favorire la decontrazione cutanea. To significantly reduce wrinkles and regain smoother skin, it is necessary to act on the main mechanism responsible for the formation of wrinkles and promote skin decontraction.
Allo stato dell’arte sono note diverse preparazioni che prevedono l’utilizzo di cannabidiolo come principio attivo, per rilassare la muscolatura del viso e limitare la formazione di rughe. At the state of the art, various preparations are known that involve the use of cannabidiol as an active ingredient, to relax the facial muscles and limit the formation of wrinkles.
Il principale svantaggio dei preparati noti allo stato dell’arte è legato all’assorbimento del principio attivo, in quanto tali preparati non permettono un assorbimento che consenta una azione anti rughe efficace. The main disadvantage of the preparations known in the state of the art is related to the absorption of the active ingredient, as these preparations do not allow an absorption that allows an effective anti-wrinkle action.
Per risolvere tale problematica la tendenza dei preparati noti allo stato dell’arte è di aumentare la dose di principio attivo, ma risulta evidente come tale soluzione sia difficilmente sostenibile, sia da un punto di vista di preparazione che da un punto di vista economico. To solve this problem, the tendency of preparations known in the state of the art is to increase the dose of the active ingredient, but it is clear that this solution is difficult to sustain, both from a preparation point of view and from an economic point of view.
Esiste dunque una necessità non soddisfatta dai preparati noti allo stato dell’arte, di ottenere un preparato che presenti una composizione tale da garantire un elevato assorbimento del principio attivo utilizzato, aumentando l’efficacia del preparato stesso. There is therefore a need not satisfied by the preparations known in the state of the art, to obtain a preparation that has a composition such as to ensure a high absorption of the active ingredient used, increasing the effectiveness of the preparation itself.
La presente invenzione consegue gli scopi di cui sopra realizzando un preparato come descritto in precedenza, in cui il Cannabidiolo è previsto in associazione di uno o più ingredienti scelti nel gruppo dei terpeni. The present invention achieves the above purposes by making a preparation as described above, in which the Cannabidiol is provided in association with one or more ingredients selected from the group of terpenes.
A livello naturale, il cannabidiolo all’interno della pianta è costituito da un fito-complesso, ossia è presente cannabidiolo in combinazione a terpeni, biomolecole costituite da multipli dell'unità isoprenica, ottenuti nei sistemi biologici dalla reazione di più unità di IPP (isopentenil pirofosfato) e di DMAPP (dimetilallil pirofosfato), che hanno come funzione quella di potenziare il principio attivo. At a natural level, the cannabidiol inside the plant consists of a phyto-complex, i.e. cannabidiol is present in combination with terpenes, biomolecules consisting of multiples of the isoprene unit, obtained in biological systems from the reaction of several units of IPP (isopentenyl pyrophosphate) and DMAPP (dimethylallyl pyrophosphate), which have the function of enhancing the active ingredient.
Il preparato oggetto della presente invenzione si prefigge dunque lo scopo di ricreare l’ambiente del fito complesso, prevedendo come componenti sia cannabidiolo che terpeni, in modo da potenziare l’effetto del cannabidiolo. The preparation object of the present invention therefore aims to recreate the environment of the phyto complex, providing both cannabidiol and terpenes as components, in order to enhance the effect of cannabidiol.
In accordo a tale configurazione, e grazie a caratteristiche che verranno successivamente descritte, il preparato oggetto della presente invenzione non ha solamente un effetto antirughe, ma consente di curare dermatiti e infiammazioni cutanee e risulta particolarmente efficace contro la secrezione di sostanze che generano l’acne. In accordance with this configuration, and thanks to characteristics that will be described later, the preparation object of the present invention not only has an anti-wrinkle effect, but allows the treatment of dermatitis and skin inflammations and is particularly effective against the secretion of substances that generate acne. .
Oltre a potenziare l’effetto del principio attivo utilizzato, uno degli scopi principali della presente domanda di brevetto è aumentare l’assorbimento a livello cutaneo del principio attivo. In addition to enhancing the effect of the active ingredient used, one of the main purposes of this patent application is to increase the absorption of the active ingredient in the skin.
Per questo motivo, secondo una forma esecutiva preferita, il preparato comprende oli insaturi. For this reason, according to a preferred embodiment, the preparation comprises unsaturated oils.
Il cannabidiolo è infatti una sostanza lipofila, si solubilizza all’interno di sostanze oleose. Cannabidiol is in fact a lipophilic substance, it solubilizes within oily substances.
Come verrà descritto successivamente relativamente al metodo di preparazione, il cannabidiolo non solo è solubilizzato in sostanze oleose, ma il preparato oggetto della presente invenzione prevede una aggiunta di sostanze oleose con componenti oleose preventivamente ozonizzate. As will be described later in relation to the preparation method, cannabidiol is not only solubilized in oily substances, but the preparation object of the present invention provides for an addition of oily substances with previously ozonated oily components.
Studi clinici hanno dimostrato che l’ozonizzazione delle sostanze oleose migliora la diffusione del principio attivo, in quanto l’ozono provoca irrorazione dei vasi, e dilatazione, migliorandone la penetrazione. Clinical studies have shown that the ozonation of oily substances improves the diffusion of the active ingredient, as ozone causes blood vessels to spray and dilate, improving their penetration.
Inoltre l’ozonizzazione stabilizza il cannabidiolo all’interno del preparato perché l’ozono forma legami che consentono di ancorare il cannabidiolo ai terpeni. In addition, ozonation stabilizes the cannabidiol within the preparation because ozone forms bonds that allow the cannabidiol to be anchored to the terpenes.
Dunque secondo una forma esecutiva preferita, il preparato oggetto della presente invenzione prevede una combinazione di cannabidiolo, terpeni e sostanze oleose ozonizzate. Therefore, according to a preferred embodiment, the preparation object of the present invention provides a combination of cannabidiol, terpenes and ozonized oily substances.
Tale complesso consente di ottenere risultati sorprendenti sia a livello di azione antirughe che per la cura di dermatiti, infiammazioni o malattie cutanee. This complex allows to obtain surprising results both in terms of anti-wrinkle action and for the treatment of dermatitis, inflammation or skin diseases.
Dagli studi condotti sul preparato oggetto della presente invenzione, è risultato come l’utilizzo di sostanze oleose ozonizzate favorisca l’assorbimento da parte dell’epidermide non solo del cannabidiolo, ma di un qualsivoglia principio attivo. From the studies conducted on the preparation object of the present invention, it was found that the use of ozonized oily substances favors the absorption by the epidermis not only of cannabidiol, but of any active ingredient.
La presente invenzione dunque riguarda anche un preparato che prevede l’utilizzo di un principio attivo in combinazione ad una sostanza oleosa ozonizzata, indipendentemente dal metodo di ozonizzazione utilizzato. The present invention therefore also relates to a preparation that provides for the use of an active ingredient in combination with an ozonated oily substance, regardless of the ozonation method used.
Preferibilmente è possibile prevedere uno specifico procedimento di ozonizzazione, che risulta particolarmente efficace utilizzando oli vegetali, quali olio di Neem, olio di pesca, olio di lino, olio di rosa mosqueta. Preferably it is possible to provide a specific ozonation process, which is particularly effective using vegetable oils, such as Neem oil, peach oil, linseed oil, rosehip oil.
Tale procedimento prevede l’esposizione dell’olio ad un continuo flusso di ozono sotto un campo magnetico pulsato a basse temperature. This procedure involves exposing the oil to a continuous flow of ozone under a pulsed magnetic field at low temperatures.
All’interno dell’applicatore deve essere presente un solenoide (un magnete di forma circolare) del diametro base di qualche centimetro dal quale si genera un campo magnetico a bassa frequenza, tra 1hz e 50hz, ed a bassa temperatura. Quindi si inserisce un flusso di ozono nell’olio all’interno del solenoide attraversato da una corrente continua iniziale ovvero un tipo di corrente elettrica con polarità fissa ed invariabile caratterizzata dallo spostamento ordinato delle cariche elettriche dell’ozono che attraversano la superficie nell’unità di tempo. A questo andamento si introduce quello alternato che corrisponde ad una inversione dell’andamento delle cariche elettriche conseguente ad inversione dei poli, rispettivamente positivo e negativo, che avviene con periodicità fissa intorno ai 50/60HZ. Studi scientifici hanno dimostrato che l’ozono, per quanto altamente instabile come gas, possa essere intrappolato all’interno di oli vegetali composti da acidi grassi saturi ed insaturi che trattengono l’ozono prolungandone la sua azione. Ovviamente maggiore sarà il numero di acidi grassi insaturi maggiore sarà la capacità di trattenere ozono, che darà luogo agli ozonidi. Inside the applicator there must be a solenoid (a circular magnet) with a base diameter of a few centimeters from which a low-frequency magnetic field is generated, between 1hz and 50hz, and at low temperature. Then a flow of ozone is inserted into the oil inside the solenoid crossed by an initial direct current or a type of electric current with fixed and invariable polarity characterized by the ordered displacement of the electric charges of the ozone that cross the surface in the unit of time. The alternating trend is introduced to this trend, which corresponds to an inversion of the trend of the electrical charges resulting from the inversion of the poles, respectively positive and negative, which occurs with a fixed periodicity of around 50 / 60HZ. Scientific studies have shown that ozone, although highly unstable as a gas, can be trapped inside vegetable oils composed of saturated and unsaturated fatty acids that retain ozone, prolonging its action. Obviously, the greater the number of unsaturated fatty acids, the greater the ability to retain ozone, which will give rise to ozonides.
Processo formazione ozonide: Ozonide formation process:
- attacco elettrofilo del doppio legame insaturo all’ozono - electrophilic attack of the unsaturated double bond on ozone
Successivo riassestamento e formazione dell’ozonuro secondario stabile. Subsequent readjustment and formation of the stable secondary ozonide.
Di conseguenza la breve catena degli acidi grassi ottenuta dalla saturazione dell’ozono, e l’idrofilia dell’olio ottenuta dalla frammentazione data dall’inserimento dell’ozono polare, consentono alla nuova molecola di fondersi con la parete cellulare e riversarsi nel citosol stimolando mediante una serie di meccanismi biochimici la cellula alla difesa naturale dalle sostanze dannose (azione antiradicalica) ed aumentando il contenuto energetico come ATP. Quindi l’olio ozonizzato ottenuto possiede in genere azione battericida, antivirale, antiinfiammatoria fotoprotettiva e riparatrice/rigenerativa dei tessuti. Consequently, the short chain of fatty acids obtained from ozone saturation, and the hydrophilicity of the oil obtained from the fragmentation given by the insertion of polar ozone, allow the new molecule to fuse with the cell wall and pour into the cytosol, stimulating by means of a series of biochemical mechanisms the cell to natural defense from harmful substances (anti-radical action) and increasing the energy content such as ATP. Therefore, the ozonated oil obtained generally has bactericidal, antiviral, anti-inflammatory, photoprotective and tissue repair / regenerative action.
Tale olio ozonizzato potrà poi essere aggiunto alla miscela composta da cannbisiolo e terpeni, come verrà descritto successivamente. This ozonated oil can then be added to the mixture composed of cannbisiol and terpenes, as will be described later.
Come anticipato, sulla base degli esperimenti condotti, gli olii insaturi sono i preferiti da prevedere all’interno del parato oggetto della presente invenzione. As anticipated, on the basis of the experiments conducted, unsaturated oils are the preferred ones to be provided within the wall object of the present invention.
Tra gli olii insaturi l’olio di oliva risulta essere l’olio di elezione, così come l’olio di girasole. Among the unsaturated oils, olive oil appears to be the oil of choice, as well as sunflower oil.
Tuttavia, poiché il preparato oggetto della presente invenzione prevede un uso principalmente cosmetico, secondo una possibile forma esecutiva, viene utilizzato olio di Neem ozonizzato. However, since the preparation object of the present invention envisages a mainly cosmetic use, according to a possible embodiment, ozonated Neem oil is used.
L’olio di Neem è infatti un olio altamente insaturo, che chimicamente ha una struttura simile all’olio di oliva. Neem oil is in fact a highly unsaturated oil, which chemically has a structure similar to olive oil.
Secondo un perfezionamento, il Cannabidiolo è presente in una percentuale compresa tra lo 0,05% e lo 0,5% rispetto al peso totale del preparato, preferibilmente in una percentuale compresa tra lo 0,1% e lo 0,3%, in particolare lo 0,2%. According to an improvement, Cannabidiol is present in a percentage between 0.05% and 0.5% with respect to the total weight of the preparation, preferably in a percentage between 0.1% and 0.3%, in particularly 0.2%.
Vantaggiosamente la componente oleosa ozonizzata è presente in una percentuale compresa tra o 0,01% e il 20% del peso totale del preparato Advantageously, the ozonated oily component is present in a percentage between 0.01% and 20% of the total weight of the preparation
La percentuale della componente oleosa varia anche in base alla natura del preparato, ossia se quest’ultimo è previsto in forma di gel, crema, unguento, emulsione o olio. The percentage of the oily component also varies according to the nature of the preparation, ie whether the latter is provided in the form of gel, cream, ointment, emulsion or oil.
A puro titolo di esempio, preferibilmente la componente oleosa ozonizzata è presente in una percentuale di circa il 5% se il preparato è previsto sotto forma di olio, mentre è previsto in una percentuale di circa lo 0,01% se il preparato è previsto sotto forma di crema. Purely by way of example, preferably the ozonated oily component is present in a percentage of about 5% if the preparation is provided in the form of oil, while it is expected in a percentage of about 0.01% if the preparation is provided under cream form.
In base al procedimento di ozonizzazione infatti, l’olio ozonizzato può generare odori sgradevoli, particolare da non sottovalutare in cosmesi. In fact, according to the ozonation process, ozonated oil can generate unpleasant odors, a particular not to be underestimated in cosmetics.
Per questo motivo preferibilmente il preparato oggetto della presente invenzione può essere previsto in forma di olio secco, con percentuali più elevate di componente oleosa ozonizzata, e in forma di crema, con percentuali minori di componente oleosa ozonizzata. For this reason, the preparation object of the present invention can preferably be provided in the form of dry oil, with higher percentages of ozonated oily component, and in the form of cream, with lower percentages of ozonated oily component.
Poiché la componente oleosa ozonizzata ha un elevato potere antirughe, è ad esempio possibile prevedere un kit comprendente un olio secco che viene applicato a zone di particolare tensione muscolare (come il contorno occhi e il contorno bocca), e una crema spalmata nelle restanti parti e/o sopra le zone di maggiore tensione muscolare. Since the ozonated oily component has a high anti-wrinkle power, it is for example possible to provide a kit comprising a dry oil that is applied to areas of particular muscular tension (such as the eye contour and the mouth contour), and a cream spread on the remaining parts and / or over the areas of greatest muscle tension.
Successivamente verranno descritti alcuni esempi esecutivi di metodologie di realizzazione del preparato oggetto della presente invenzione, ma si anticipa che per l’ottenimento dell’olio è preferibile inserire conservanti ed emulsionanti, come ad esempio esteri, per sgrassare la fase oleosa e rendere il preparato più secco, mentre per variare la consistenza della crema vengono previste sostanze emulsionanti e texturizzanti. Subsequently, some executive examples of methods for making the preparation object of the present invention will be described, but it is anticipated that for obtaining the oil it is preferable to insert preservatives and emulsifiers, such as esters, to degrease the oily phase and make the preparation more dry, while emulsifying and texturizing substances are used to vary the consistency of the cream.
Infine secondo una possibile variante esecutiva, il preparato oggetto della presente invenzione può prevedere che almeno il principio attivo del cannabidiolo sia previsto incorporato all’interno di niosomi. Finally, according to a possible executive variant, the preparation object of the present invention can provide that at least the active ingredient of cannabidiol is expected to be incorporated within niosomes.
Tale configurazione risulta particolarmente efficace per l’utilizzo del preparato oggetto della presente invenzione per la cura di patologie, quali dermatiti o infiammazioni epidermiche. This configuration is particularly effective for the use of the preparation object of the present invention for the treatment of pathologies, such as dermatitis or epidermal inflammation.
Poiché la sola presenza della componente oleosa ozonizzata aumenta in maniera considerevole l’efficacia del principio attivo, la presente invenzione ha per oggetto anche un preparato ad uso topico per trattamenti dermatologici comprendente come principale principio attivo cannabidiolo in associazione ad una o più componenti oleose ozonizzate. Since the mere presence of the ozonated oily component considerably increases the effectiveness of the active ingredient, the present invention also relates to a preparation for topical use for dermatological treatments including cannabidiol as the main active ingredient in association with one or more ozonated oily components.
Tale preparato può presentare una o più delle caratteristiche descritte in precedenza. This preparation can have one or more of the characteristics described above.
Infine visti gli aspetti vantaggiosi appena descritti, la presente invenzione ha per oggetto anche un metodo di preparazione di un preparato ad uso topico per trattamenti dermatologici. Finally, given the advantageous aspects described above, the present invention also relates to a method for preparing a preparation for topical use for dermatological treatments.
In particolare il metodo comprende i seguenti passi: In particular, the method includes the following steps:
a) solubilizzazione di cannabidiolo all’interno di una componente oleosa, a) solubilization of cannabidiol within an oily component,
b) aggiunta di uno o più ingredienti scelti nel gruppo dei terpeni, b) addition of one or more ingredients selected from the group of terpenes,
c) aggiunta di una o più componenti oleose ozonizzate. c) addition of one or more ozonized oily components.
I passi di metodo appena descritti consentono di realizzare una versione esecutiva preferita del preparato oggetto della presente invenzione, che prevede una combinazione di cannabidiolo, terpeni e componenti oleose ozonizzate, sia in forma di crema che in forma di olio. The method steps described above allow to realize a preferred embodiment version of the preparation object of the present invention, which provides a combination of cannabidiol, terpenes and ozonated oily components, both in the form of cream and in the form of oil.
Oltre a tali componenti, come descritto in precedenza, il preparato oggetto della presente invenzione può presentare diverse tipologie di eccipienti, che modificano le temperature di preparazione e lavorazione del preparato stesso. In addition to these components, as previously described, the preparation object of the present invention can have different types of excipients, which modify the preparation and processing temperatures of the preparation itself.
L’efficacia del preparato e la buona riuscita del metodo oggetto della presente invenzione dipendono fortemente dalle temperature alle quali eseguire tali passi, soprattutto per la natura delle componenti utilizzate. The effectiveness of the preparation and the success of the method object of the present invention strongly depend on the temperatures at which to perform these steps, especially due to the nature of the components used.
Infatti secondo una prima forma esecutiva, il passo b) relativo all’aggiunta di uno o più ingredienti scelti nel gruppo dei terpeni e il passo c) relativo all’aggiunta di una o più componenti oleose ozonizzate, avvengono ad una temperatura inferiore a 45°C. In fact, according to a first embodiment, step b) relating to the addition of one or more ingredients selected from the group of terpenes and step c) relating to the addition of one or more ozonated oily components, take place at a temperature below 45 ° C.
A temperature più elevate, ad esempio a temperature necessarie per realizzare una emulsione per una crema, pari a circa 70°C, sia l’ozono, che i terpeni, che sono componenti fortemente volatili, evaporerebbero, rendendo vano il loro contributo e i vantaggi di assorbimento ed efficacia del preparato. At higher temperatures, for example at temperatures necessary to make an emulsion for a cream, equal to about 70 ° C, both the ozone and the terpenes, which are highly volatile components, would evaporate, making their contribution and the advantages of absorption and efficacy of the preparation.
Secondo una possibile variante attuativa, volta ad evitare deterioramenti del principio attivo del cannabidiolo, il passo a) relativo alla solubilizzazione di quest’ultimo, avviene ad una temperatura compresa tra 30°C e 50°C. According to a possible variant of implementation, aimed at avoiding deterioration of the active ingredient of cannabidiol, step a) relating to the solubilization of the latter takes place at a temperature between 30 ° C and 50 ° C.
Come anticipato il preparato oggetto della presente invenzione preferibilmente è previsto sotto forma di crema o di olio secco, di cui verranno descritti due esempi esecutivi. As anticipated, the preparation object of the present invention is preferably provided in the form of a cream or dry oil, of which two executive examples will be described.
Nel primo caso, è necessario prevedere un passo di realizzazione di una emulsione e successiva incorporazione della solubilizzazione ottenuta al passo a) all’interno dell’emulsione. In the first case, it is necessary to provide a step for making an emulsion and subsequent incorporation of the solubilization obtained in step a) inside the emulsion.
Vantaggiosamente, la realizzazione di una emulsione prevede i seguenti sottopassi: Advantageously, the realization of an emulsion provides for the following underpasses:
- riscaldamento ad una temperatura compresa tra 65°C e 85°C di una determinata quantità di una componente lipofila, - heating at a temperature between 65 ° C and 85 ° C of a certain quantity of a lipophilic component,
- aggiunta di una medesima quantità di acqua, - al raggiungimento della temperatura di transizione di fase, aggiunta di acqua al fine di ottenere l’emulsione. - adding the same amount of water, - on reaching the phase transition temperature, adding water in order to obtain the emulsion.
Verranno qui di seguito descritte alcune possibili forme esecutive e corrispondenti metodi di realizzazione, del preparato oggetto della presente invenzione. Some possible embodiments and corresponding manufacturing methods of the preparation object of the present invention will be described below.
In particolare, tali forme esecutive riguardano la realizzazione del preparato sotto forma di olio secco e sotto forma di crema. In particular, these embodiments relate to the preparation of the preparation in the form of dry oil and in the form of cream.
Tali forme non sono da intendersi limitative al concetto inventivo della presente domanda di brevetto, che prevede di realizzare un preparato ad uso topico volto a massimizzare l’azione del principio attivo, in particolare cannabidiolo. These forms are not to be construed as limiting the inventive concept of this patent application, which provides for the creation of a preparation for topical use aimed at maximizing the action of the active ingredient, in particular cannabidiol.
In base a quanto descritto in precedenza infatti, il principio attivo cannabidiolo viene previsto in associazione a terpeni e sostanze oleose ozonizzate, in alternativa od in combinazione. In fact, on the basis of what has been described above, the active ingredient cannabidiol is provided in association with terpenes and ozonized oily substances, alternatively or in combination.
Realizzazione del preparato come olio secco e composizione Realization of the preparation as dry oil and composition
Pesare tutti i componenti e solubilizzare cannabidiolo e composti più solidi sotto leggero riscaldamento e sotto agitazione sino a completa dissoluzione. Solubilizzare Phosphatidylcholine in Isopropyl Myristate e ethylhexyl stearate, raffreddare e dissolvere sotto lenta agitazione. Controllare che la temperatura sia sotto i 38 °C e aggiungere, sotto agitazione: Gossypium herbaceum seed oil, Helianthus annum oil, Calendula officinlis extract, Chamomilla Recutita extract, Bisabolol, Vitis vinifera seed oil, Ribes nigrum seed oil, Hydrogenated ethyhexyl olivate, Hydrogenated olive oil unsaponifiable, Persea gratissima oil, Isopropyl palmitate, Phenylethyl alcohol, Olea Europaea Oil Unsaponifiables, Borago Officinalis Seed Oil, Dicaprylyl Ether, Fish glycerides e il profumo.. Introdurre alla fine tutti i terpeni: Alpha-pinene, Limonene, Myrcene, B-Cariophyllene e Linalolo, per ultimo e sotto lenta agitazione aggiungere l'olio di Neem ozonizzato. miscelare fino ad omogenità. Confezionare. Weigh all the components and solubilize cannabidiol and more solid compounds under gentle heating and stirring until completely dissolved. Solubilize Phosphatidylcholine in Isopropyl Myristate and ethylhexyl stearate, cool and dissolve under slow stirring. Check that the temperature is below 38 ° C and add, while stirring: Gossypium herbaceum seed oil, Helianthus annum oil, Calendula officinlis extract, Chamomilla Recutita extract, Bisabolol, Vitis vinifera seed oil, Ribes nigrum seed oil, Hydrogenated ethyhexyl olivate, Hydrogenated olive oil unsaponifiable, Persea gratissima oil, Isopropyl palmitate, Phenylethyl alcohol, Olea Europaea Oil Unsaponifiables, Borago Officinalis Seed Oil, Dicaprylyl Ether, Fish glycerides and the perfume. Introduce at the end all the terpenes: Alpha-pinene, Limonene, Myrcene, B -Cariophyllene and Linalool, lastly and under slow stirring add the ozonated Neem oil. mix until homogeneous. To pack.
Sempre utilizzando il medesimo procedimento, ma variando gli ingredienti, è possibile prevedere la seguente composizione: Still using the same procedure, but varying the ingredients, it is possible to provide the following composition:
Dicaprylyl ether, Isopropyl myristate, Ethylhexyl stearate, Hydrogenated ethylhexyl olivate, Isopropyl palmitate, Limonene, Borago officinalis seed oil, Ozonized Azadirachta indica seed oil, Ribes nigrum fruit oil, Vitis vinifera seed oil, Gossypium herbaceum seed oil, Helianthus annuus seed oil, Olea europaea oil unsaponifiables, Persea gratissima oil, Parfum, Phosphatidylcholine, Bisabolol, Hydrogenated olive oil unsaponifiables, Phenethyl alcohol, Illicium verum fruit/seed oil, Calendula officinalis flower extract, Fish glycerides, Cannabidiol, Citrus nobilis peel oil, Citrus aurantium dulcis peel oil, Chamomilla recutita flower extract, Linalool, Citrus aurantium amara peel oil, Citrus grandis peel oil, Citrus aurantium bergamia fruit oil, Citral, Geraniol, Citrus limon peel oil, Beta-caryophyllene, l-Alpha-pinene, Myrcene. Dicaprylyl ether, Isopropyl myristate, Ethylhexyl stearate, Hydrogenated ethylhexyl olivate, Isopropyl palmitate, Limonene, Borago officinalis seed oil, Ozonized Azadirachta indica seed oil, Ribes nigrum fruit oil, Vitis vinifera seed oil, Gossypium herbaceum seed oil, Helthus annea seed oil, Olthus annea seed oil europaea oil unsaponifiables, Persea gratissima oil, Parfum, Phosphatidylcholine, Bisabolol, Hydrogenated olive oil unsaponifiables, Phenethyl alcohol, Illicium verum fruit / seed oil, Calendula officinalis flower extract, Fish glycerides, Cannabidiol, Citrus nobilis peel oil, Citrus pe aurantium oil dulc Chamomilla recutita flower extract, Linalool, Citrus aurantium amara peel oil, Citrus grandis peel oil, Citrus aurantium bergamia fruit oil, Citral, Geraniol, Citrus limon peel oil, Beta-caryophyllene, l-Alpha-pinene, Myrcene.
L’olio ozonizzato potrebbe anche chiamarsi Ozonized neem oil e quindi andrebbe registrato con entrambi i nomi. The ozonated oil could also be called Ozonized neem oil and therefore should be registered with both names.
Realizzazione del preparato come crema e composizione Realization of the preparation as a cream and composition
Scaldare le due fasi separatamente fino a solubilizzazione. Heat the two phases separately until solubilization.
Fase A: Ethylhexyl starate, Cetearyl Ethylhexanoate, Isopropyl Myristate, Dicaprylyl Ether, cannabidiolo, Polysorbate 80, Phenoxyethanol, Ethylhexyl glycerin, PEG-120 Methyl Glucose Dioleate, Cyclopentasiloxane, Dimethiconol, Hydrogenated ethyhexyl olivate, Hydrogenated olive oil unsaponifiable. Raffreddare leggermente e aggiungere Linum usitatissium seed oil, Ribes nigrum seed oil. Phase A: Ethylhexyl starate, Cetearyl Ethylhexanoate, Isopropyl Myristate, Dicaprylyl Ether, cannabidiol, Polysorbate 80, Phenoxyethanol, Ethylhexyl glycerin, PEG-120 Methyl Glucose Dioleate, Cyclopentasiloxane, Dimethiconol unspoiled oil-hydrogenated hydrogenifiable. Cool slightly and add Linum usitatissium seed oil, Ribes nigrum seed oil.
Fase B: pesare e miscelare Aqua, glycerin, Glucose, Sorbitol, Sodium Glutamate, Urea, Sodium PCA, Glycine, Lactic Acid, Hydrolyzed Wheat Protein,Panthenol. Unire le due fasi, sotto turbo per il tempo necessario per far avvenire l'emulsione. Aggiungere sotto turbo cellulosa e Hydroxyethyl Acrylate/Sodium Acryloyldimethyl Taurate Copolymer. Una volta omogenato aggiungere sotto lenta agitazione il profumo e i terpeni: Alpha-pinene, Limonene, Myrcene, B-Cariophyllene e Linalolo, per ultimo e sotto lenta agitazione aggiungere l'olio di Neem ozonizzato. Confezionare. Phase B: Weigh and mix Aqua, glycerin, Glucose, Sorbitol, Sodium Glutamate, Urea, Sodium PCA, Glycine, Lactic Acid, Hydrolyzed Wheat Protein, Panthenol. Combine the two phases, under turbo for the time necessary for the emulsion to take place. Add under turbo cellulose and Hydroxyethyl Acrylate / Sodium Acryloyldimethyl Taurate Copolymer. Once homogenized, add the perfume and terpenes under slow stirring: Alpha-pinene, Limonene, Myrcene, B-Cariophyllene and Linalool, lastly and under slow stirring add the ozonated Neem oil. To pack.
Sempre utilizzando il medesimo procedimento, ma variando gli ingredienti, è possibile prevedere la seguente composizione: Still using the same procedure, but varying the ingredients, it is possible to provide the following composition:
Aqua, Dicaprylyl ether, Hydrogenated ethylhexyl olivate, Cetearyl ethylhexanoate, Glycerin, Polysorbate 80, Ribes nigrum fruit oil, PEG-120 methyl glucose dioleate, Cellulose, Ethylhexyl stearate, Hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, Parfum, Phenoxyethanol, Cyclopentasiloxane, Hydrogenated olive oil unsaponifiables, Linum usitatissimum seed oil, Cannabidiol, Isopropyl myristate, Glucose, Ethylhexylglycerin, Sorbitol, Dimethiconol, Sodium glutamate, Urea, Tocopherol, Lecithin, Ascorbyl palmitate, Citric acid, Glycine, Hydrolyzed wheat protein, Lactic acid, Sodium PCA, Ozonized Azadirachta indica seed oil, Panthenol, Linalool, Beta-caryophyllene, l-Alpha-pinene, Myrcene, Limonene. Aqua, Dicaprylyl ether, Hydrogenated ethylhexyl olivate, Cetearyl ethylhexanoate, Glycerin, Polysorbate 80, Ribes nigrum fruit oil, PEG-120 methyl glucose dioleate, Cellulose, Ethylhexyl stearate, Hydroxyethyl acrylate / sodium acryloyldimymer hydrogen chloride, hydroxyethyl acrylate / sodium acryloyldimymer chloride, hydrogenated chloride hydrogen chloride oil unsaponifiables, Linum usitatissimum seed oil, Cannabidiol, Isopropyl myristate, Glucose, Ethylhexylglycerin, Sorbitol, Dimethiconol, Sodium glutamate, Urea, Tocopherol, Lecithin, Ascorbyl palmitate, Citric acid, Glycine protein, HydzonAtic acidized, Sodium acidized PC indicates seed oil, Panthenol, Linalool, Beta-caryophyllene, l-Alpha-pinene, Myrcene, Limonene.
L’olio ozonizzato potrebbe anche chiamarsi Ozonized neem oil e quindi andrebbe registrato con entrambi i nomi. The ozonated oil could also be called Ozonized neem oil and therefore should be registered with both names.
Claims (10)
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102019000014568A IT201900014568A1 (en) | 2019-08-09 | 2019-08-09 | Topical preparation for dermatological treatments |
| PCT/IB2020/052022 WO2020178805A2 (en) | 2019-03-07 | 2020-03-09 | Preparation for topical use for dermatological treatments |
| US17/436,636 US20220151951A1 (en) | 2019-03-07 | 2020-03-09 | Preparation for topical use for dermatological treatments |
| EP20718768.3A EP3934621B1 (en) | 2019-03-07 | 2020-03-09 | Preparation for topical use for dermatological treatments |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IT102019000014568A IT201900014568A1 (en) | 2019-08-09 | 2019-08-09 | Topical preparation for dermatological treatments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IT201900014568A1 true IT201900014568A1 (en) | 2021-02-09 |
Family
ID=69024541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IT102019000014568A IT201900014568A1 (en) | 2019-03-07 | 2019-08-09 | Topical preparation for dermatological treatments |
Country Status (1)
| Country | Link |
|---|---|
| IT (1) | IT201900014568A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4451480A (en) * | 1982-04-16 | 1984-05-29 | James Howard Brown | Method of treating acne using ozonized materials |
| WO2019136351A1 (en) * | 2018-01-05 | 2019-07-11 | Altus Labs, Llc | Personal care compositions |
-
2019
- 2019-08-09 IT IT102019000014568A patent/IT201900014568A1/en unknown
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4451480A (en) * | 1982-04-16 | 1984-05-29 | James Howard Brown | Method of treating acne using ozonized materials |
| WO2019136351A1 (en) * | 2018-01-05 | 2019-07-11 | Altus Labs, Llc | Personal care compositions |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104274358B (en) | A kind of scalp maintenance type hair-washing composition and preparation method containing plants essential oil | |
| JP2010132629A (en) | External composition for skin | |
| CN103989601B (en) | A kind of shining tender skin face cream of face moisturizing and preparation method thereof | |
| BG1687U1 (en) | Cosmetic composition | |
| KR102354954B1 (en) | Fish Oil Topical Composition | |
| EP2763686A1 (en) | Composition for the treatment of skin lesions | |
| CN106727122B (en) | Skin care emulsion for fading striae gravidarum and preparation method thereof | |
| EP3934621B1 (en) | Preparation for topical use for dermatological treatments | |
| DE202005007603U1 (en) | Composition for oral or topical administration, e.g. as a dietary supplement or dietetic food, shower gel, body lotion, cream or care concentrate, comprises argan oil and nigella oil | |
| CN105963163B (en) | A kind of dewrinkling spot-eliminating Essence and preparation method thereof | |
| IT201900014568A1 (en) | Topical preparation for dermatological treatments | |
| IT201900003349A1 (en) | Topical preparation for dermatological treatments | |
| KR100826310B1 (en) | Cosmetic composition | |
| CA3188531A1 (en) | Topical compositions, process of large-scale manufacture, and method of use | |
| FR2913602A1 (en) | Composition, useful e.g. for care of skin damaged by aesthetic treatment, cosmetic/therapeutic such as surgical interventions, laser treatment, dermabrasions and peelings, comprises peptide associated with oil having alpha-linolenic acid | |
| KR20120038699A (en) | A cosmetic composition containing bee venom | |
| RU2242217C1 (en) | Preparation for preventing and treating capillary cutaneous lesions (teleangioectasias) | |
| RU2602691C2 (en) | Cosmetic product | |
| RU2787363C1 (en) | Mousse for body skin care | |
| RU2186561C2 (en) | Cream for dry and normal face skin | |
| RU2242215C1 (en) | Purifying and toning up "diamant" milk for dry and sensitive skin | |
| CN105726348B (en) | Cosmetic composition | |
| RU2212229C1 (en) | Diurnal recovering cream | |
| RU2170569C1 (en) | Cosmetic cream | |
| KR20100094109A (en) | Functional skin lotion including date |